Context The molecular subtype of breast tumours plays a major role

Context The molecular subtype of breast tumours plays a major role in cancer prognosis and treatment options. There was no significant association found between SES and tumour subtype in French ladies at diagnosis. Ladies more than 75 years were less likely to have a TN and HR+/HER2+ breast tumor (OR = 0.66; CI95% = [0.46C0.94] and OR = 0.51; CI95% = [0.37C0.70] respectively). Ladies with TN tumour subtype experienced significantly less lymph node invasion when compared to HR+/HER2- subtype (OR = 0.71; CI95% = [0.54C0.92]). Summary No significant association was found between socioeconomic status and molecular subtype. Further studies are needed to clarify the mechanisms associated with developing each tumour subtype. Intro Breast tumor is the most common tumor among women in the entire world [1]. In France, about 50 000 ladies are diagnosed with breast tumor each year [2]. Breast tumours are classified into one of four clinically relevant molecular subtypes based on the joint status of the hormone receptors (oestrogen and progesterone) and human being epidermal growth factors receptor 2 (HER2) [3,4]. The hormone receptors (HR) and HER2 receptors are said to be positive if they are overexpressed in a tumour cell. The HR-positive tumours are the most common at diagnosis (80%), and the HER2-positive represents about 15C20% [5]. Receptor screening is usually readily available and performed routinely during breast malignancy diagnosis in France. The information on receptors is usually of clinical importance since treatment options are selected based on the joint receptor status. Each subtype has its own unique histological profile and risk factors [2]. The HER2+ tumours are known to be very aggressive and have poor survival in women [3]. Nowadays, the HR+/HER2+ subtype CP-690550 has a better prognosis, particularly in metastatic tumours because it has molecular targets for hormone therapy as well as other targeted treatments like Trastuzumab (HerceptinTM) [4]. Tumours which are unfavorable for both hormone receptors (HR) and HER2 receptor are called triple unfavorable tumours (TN). These TN tumours have the worst prognosis and impact more often underprivileged women in the USA [5,6]. Socioeconomic status influences the exposure to several risk factors which could change tumour biology [7,8]. It has been shown that women in high poverty areas tend to secrete more oestrogen when compared to women with a more affluent socioeconomic status [8]. Few studies have looked at the association between socioeconomic status and tumour subtypes [9C14]. Among these studies, there have been registry based analyses where a significant association between the SES and the breast malignancy subtype in American women was observed, in particular among the TN cases who experienced higher odds of being in the lowest socioeconomic stratum when compared to the other subtypes To this date no study has been carried out investigating this association in women residing in France. Our objective is to study the association between socioeconomic status and breast malignancy subtype at diagnosis among women in the French county of C?te dOr. Methods Study populace CP-690550 A population-based study was undertaken using data from your C?te dOr breast and gynaecological malignancy registry. This Breast and Gynaecological Malignancy Registry is the only one in France that focuses on breast and gynaecological cancers. It has been collecting comprehensive population-based data since 1982 in this area located in the northeast of France. Women with main invasive breast malignancy and living in the rural county of C?te dOr at CP-690550 the time of diagnosis were retrospectively determined from January 2003 to December 2013 to be included in this study. The year 2003 is the 12 months that this registry began collecting systematically data for HER2. The data extraction which was performed was anonymized prior Rabbit Polyclonal to CSGLCAT to reception of the data by the investigators and did CP-690550 not carry the patients names or personal information which could identify them (name initials). The registry has the necessary regulatory agreements to use.

Comments are closed.